Navigation Links
Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
Date:10/20/2010

ssets(3.5)(6.6)Net cash used in investing activities(139.8)(140.2)Cash flows from financing activities:Proceeds from borrowings-510.0Repayments of debt(2.6)(617.8)Purchases of treasury stock(750.0)(350.0)Exercise of stock options40.846.6Excess tax benefits from stock-based compensation arrangements

-3.2Dividends paid(54.2)(56.2)Distributions to noncontrolling interests(25.6)(23.0)Other financing activities(12.1)(16.6)Net cash used in financing activities(803.7)(503.8)Net change in cash and cash equivalents(165.0)(6.9)Cash and cash equivalents, beginning of period534.3253.9Cash and cash equivalents, end of period$  369.3$  247.0Cash paid during the period for:Interest$  118.5$  118.9Income taxes$  324.4$  283.1Notes to Financial Tables1) The computation of basic and diluted earnings per common share is as follows:Three Months EndedNine Months EndedSeptember 30,September 30,2010200920102009(in millions, except per share data)Amounts attributable to Quest Diagnostics' common stockholders:Income from continuing operations$  198.4$  191.7$  555.8$  548.6(Loss) income from discontinued operations, net of taxes(0.4)0.5(0.7)(1.1)Net income available to common stockholders$  198.0$  192.2$  555.1$  547.5Income from continuing operations$  198.4$  191.7$  555.8$  548.6Less: Earnings allocated to participating securities0.90.72.51.6Earnings available to Quest Diagnostics' common stockholders – basic and diluted


SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...  Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy ... NP001 for the treatment of amyotrophic lateral sclerosis (ALS, ... today in an oral presentation at the inaugural ... in Bloomington, Minnesota , September 17-19, ... a high dose of NP001 (2mg/kg) was associated with ...
(Date:9/17/2014)... , Sept. 17 2014 IBM (NYSE: ... is using IBM technical computing and storage technology ... cancer patients. These services deliver critically important information ... each patient,s unique cancer, which could lead to ... healthcare system in general. Today, optimal ...
(Date:9/17/2014)... Switzerland , September 17, 2014 /PRNewswire/ ... , is proud to congratulate Biocartis commitment in ... Diagnostics is a long-time investor in Biocartis as ... ™ Biocartis, fully automated, real-time PCR based ... fast and easy access to clinical molecular diagnostic ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... N.J. , March 11 Bayer HealthCare ... been granted by the U.S. Food and Drug Administration ... of pulmonary infection due to Pseudomonas aeruginosa in cystic ... granted by the European Medicines Agency. Ciprofloxacin DPI is ...
... DETROIT , March 11 Caraco Pharmaceutical ... oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, which ... from the US Food and Drug Administration (FDA) for ... an anticancer used in the treatment of colon and ...
Cached Medicine Technology:FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 2FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 3FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 4FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 5FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 6FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 7FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis 8Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 3
(Date:9/17/2014)... September 17, 2014 Kristen Yarker, MSc, RD ... parents of children 9 months to 2 years old who ... furthermore, prevent picky eaters from developing by encouraging healthy eating ... (9 months to 2 years): How to Transition From Baby ... Is Getting the Nutrition They Need)” is a new online ...
(Date:9/17/2014)... Diego, Calif. (PRWEB) September 17, 2014 ... Nature’s monthly interruptions, giving girls of all ages ... a wellness company founded by women, for women, ... Girl Uninterrupted® (http://GirlU.com) to relieve the ... cramps, bloating and irritability. , As a ...
(Date:9/17/2014)... A raucous childhood in an Italian-Polish ... form author Nancy Chovancek’s laughter-filled new book, “Angry Birds ... of short stories that prove the best way to ... positive message of empowerment and resilience, everyone can identify ... author with two books under her belt on the ...
(Date:9/17/2014)... Seattle, Wa (PRWEB) September 17, 2014 ... published by the Telegraph in August 2014, scientists made ... cure for diabetes, but still failed. The article indicates ... , Despite this existing fact, there are many forward-thinking ... for diabetes treatment in a natural way. Dr. Kenneth ...
(Date:9/17/2014)... In honor of National Health IT Week Sept. ... professionals for gaining a competitive edge in the healthcare ... demand for qualified health IT professionals are at an ... differentiating factor when filling a position. The skill most ... clinical workflow and terminology experience. American Sentinel offers ...
Breaking Medicine News(10 mins):Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 2Health News:Nutritionist Kristen Yarker Offers Parents a Fresh Approach to Prevent Picky Eaters in New Online Seminar 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4
... A protein abundantly found in treatment-resistant cancers holds an ... would normally detect DNA damage and force defective cells ... the current Cancer Cell . "Overexpression ... resistance to DNA-damaging chemotherapy, but we haven,t known how ...
... , SUNDAY, Feb. 26 (HealthDay News) -- Researchers report that ... mature into eggs that may be capable of fertilization. ... potentially lead to new reproductive technologies and possibly extend the ... that women were born with a lifetime supply of eggs, ...
... (HealthDay News) -- A potentially dangerous heart rhythm problem called ... decline in older people at risk for heart disease, new ... the Canadian Medical Association Journal , researchers analyzed data ... countries, aged 55 and older. All of the participants had ...
... lives and may save money. There are two very commonly ... it is unclear which is the most effective and provides ... BY-BAND study led by the University of Bristol and funded ... (NIHR HTA) programme will compare the outcomes of stomach bypass ...
... a new treatment for type 2 diabetes, improves blood sugar ... significantly lower risk of creating a dangerous drop in blood ... results of the phase 2 randomized trial were published Online ... diabetes is the most common form of diabetes accounting for ...
... An experimental drug improves patients, blood sugar control without ... with type 2 diabetes, according to the results of a ... more prevalent form of the disease, accounting for about 90 ... diabetes involves a gradual decline in how insulin responds to ...
Cached Medicine News:Health News:Aurora-A hinders tumor-suppressor to allow chemotherapy resistance 2Health News:Aurora-A hinders tumor-suppressor to allow chemotherapy resistance 3Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 2Health News:Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs 3Health News:Irregular Heartbeat May Predict Mental Decline in Some 2Health News:Which type of obesity surgery is best? 2Health News:Diabetes drug gets patients with Type 2 diabetes on target 2Health News:Experimental Drug Shows Promise Against Type 2 Diabetes 2Health News:Experimental Drug Shows Promise Against Type 2 Diabetes 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: